MCID: ANP008
MIFTS: 27

Anaplastic Oligoastrocytoma

Categories: Rare diseases, Neuronal diseases

Aliases & Classifications for Anaplastic Oligoastrocytoma

MalaCards integrated aliases for Anaplastic Oligoastrocytoma:

Name: Anaplastic Oligoastrocytoma 53 59 73
Amoa 59

Characteristics:

Orphanet epidemiological data:

59
anaplastic oligoastrocytoma
Age of onset: Adult; Age of death: adult;

Classifications:

Orphanet: 59  
Rare neurological diseases


External Ids:

Orphanet 59 ORPHA251663
UMLS via Orphanet 74 C0431108
ICD10 via Orphanet 34 C71.9
UMLS 73 C0431108

Summaries for Anaplastic Oligoastrocytoma

NIH Rare Diseases : 53 Anaplastic oligoastrocytoma is a brain tumor that forms when two types of cells in the brain, called oligodendrocytes and astrocytes, rapidly increase in number to form a mass.  These brain cells are known as glial cells, which normally protect and support nerve cells in the brain.  Because an oligoastrocytoma is made up of a combination of two cell types, it is known as a mixed glioma.  An oligoastrocytoma is described as anaplastic when the tumor grows quickly and the cancer cells within the tumor have the potential to spread into surrounding brain tissue or to more distant parts of the body.  Oligoastrocytomas usually occur in a part of the brain called the cerebrum and are diagnosed in adults between the ages of 30 and 50.  The exact cause of this condition is unknown.

MalaCards based summary : Anaplastic Oligoastrocytoma, also known as amoa, is related to oligoastrocytoma and leukemia. The drugs Carmustine and Dacarbazine have been mentioned in the context of this disorder. Affiliated tissues include brain, spinal cord and myeloid.

Related Diseases for Anaplastic Oligoastrocytoma

Diseases related to Anaplastic Oligoastrocytoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 16)
# Related Disease Score Top Affiliating Genes
1 oligoastrocytoma 10.5
2 leukemia 10.0
3 oligodendroglioma 10.0
4 anaplastic oligodendroglioma 10.0
5 medulloblastoma 9.9
6 mismatch repair cancer syndrome 9.9
7 leukemia, acute myeloid 9.9
8 leukemia, acute lymphoblastic 9.9
9 cysticercosis 9.9
10 lymphoblastic leukemia 9.9
11 astrocytoma 9.9
12 grade iii astrocytoma 9.9
13 paraplegia 9.9
14 myeloid leukemia 9.9
15 opsoclonus-myoclonus syndrome 9.9
16 myoclonus 9.9

Graphical network of the top 20 diseases related to Anaplastic Oligoastrocytoma:



Diseases related to Anaplastic Oligoastrocytoma

Symptoms & Phenotypes for Anaplastic Oligoastrocytoma

Drugs & Therapeutics for Anaplastic Oligoastrocytoma

Drugs for Anaplastic Oligoastrocytoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 136)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Carmustine Approved, Investigational Phase 3,Not Applicable 154-93-8 2578
2
Dacarbazine Approved, Investigational Phase 3,Phase 2,Phase 1 4342-03-4 5351166
3
Temozolomide Approved, Investigational Phase 3,Phase 2,Phase 1 85622-93-1 5394
4
Lomustine Approved, Investigational Phase 3 13010-47-4 3950
5
Benzocaine Approved, Investigational Phase 3 1994-09-7, 94-09-7 2337
6
Cyproheptadine Approved Phase 3 129-03-3 2913
7
Histamine Approved, Investigational Phase 3 75614-87-8, 51-45-6 774
8 tannic acid Approved, Nutraceutical Phase 3
9 Alkylating Agents Phase 3,Phase 2,Phase 1,Not Applicable
10 Dermatologic Agents Phase 3,Phase 1,Phase 2
11 Antineoplastic Agents, Alkylating Phase 3,Phase 2,Phase 1,Not Applicable
12 Anti-Infective Agents Phase 3,Phase 2,Phase 1
13 interferons Phase 3
14 Interferon-alpha Phase 3
15 Antiviral Agents Phase 3,Phase 1
16
Histamine Phosphate Phase 3 51-74-1 65513
17 Serotonin Agents Phase 3
18 Serotonin Antagonists Phase 3
19 Gastrointestinal Agents Phase 3,Phase 1,Not Applicable
20 Neurotransmitter Agents Phase 3,Not Applicable
21 Histamine Antagonists Phase 3
22 Histamine H1 Antagonists Phase 3
23 Anti-Allergic Agents Phase 3
24 Antipruritics Phase 3
25
Serotonin Investigational, Nutraceutical Phase 3 50-67-9 5202
26
Trioxsalen Approved Phase 2,Phase 1 3902-71-4 5585
27
Capecitabine Approved, Investigational Phase 2 154361-50-9 60953
28
Irinotecan Approved, Investigational Phase 2,Phase 1 97682-44-5, 100286-90-6 60838
29
Nintedanib Approved Phase 2 656247-17-5 56843413
30
Bevacizumab Approved, Investigational Phase 2,Phase 1 216974-75-3
31
Mannitol Approved, Investigational Phase 2 69-65-8 453 6251
32
Cetuximab Approved Phase 2 205923-56-4 56842117 2333
33
Iodine Approved, Investigational Phase 2 7553-56-2 807
34
Dexamethasone Approved, Investigational, Vet_approved Phase 2,Phase 1 50-02-2 5743
35
Acetaminophen Approved Phase 2 103-90-2 1983
36
Diphenhydramine Approved, Investigational Phase 2 147-24-0, 58-73-1 3100
37
Promethazine Approved, Investigational Phase 2 60-87-7 4927
38
Crizotinib Approved Phase 1, Phase 2 877399-52-5 11626560 10366136 10366137 10366138 10366139 10366140 10366141
39
Vorinostat Approved, Investigational Phase 1, Phase 2,Phase 2 149647-78-9 5311
40
Lenalidomide Approved Phase 2,Phase 1 191732-72-6 216326
41
Camptothecin Experimental Phase 2,Phase 1 7689-03-4
42 Podophyllotoxin Phase 1, Phase 2 518-28-5
43 Dihematoporphyrin Ether Phase 2,Phase 1
44 Photosensitizing Agents Phase 2,Phase 1
45 Keratolytic Agents Phase 1, Phase 2
46 Antimitotic Agents Phase 1, Phase 2
47 Antineoplastic Agents, Phytogenic Phase 1, Phase 2,Phase 2
48
Erlotinib Hydrochloride Phase 2,Phase 1 183319-69-9 176871
49 topoisomerase I inhibitors Phase 2,Phase 1
50 Micronutrients Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 59)
# Name Status NCT ID Phase Drugs
1 Safety and Efficacy Study of Intracranially Implanted Carmustine to Treat Newly Diagnosed Malignant Glioma Unknown status NCT01656980 Phase 3 Carmustine
2 Radiation Therapy Combined With Chemotherapy in Treating Patients With Anaplastic Astrocytoma or Mixed Gliomas Completed NCT00004259 Phase 3 BCNU 80mg/m2;TMZ 200mg/m2;CCNU;BCNU 150mg/m2;BCNU 200mg/m2;TMZ 150mg/m2 six 6-week cycles;TMZ 150mg/m2 six 8-week cycles
3 A Study on β-elemene as Maintain Treatment for Newly Diagnosed Malignant Gliomas Recruiting NCT02629757 Phase 3 β-elemene
4 A Phase III Trial on Adjuvant Temozolomide With or Without Interferon-alpha in Newly Diagnosed High-grade Gliomas Recruiting NCT01765088 Phase 3 Temozolomide;α-IFN
5 Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
6 Phase I/II Trial of Safety and Anti-tumor Efficacy of AXL1717(Picropodophyllin) in the Treatment of Recurrent Malignant Astrocytomas Unknown status NCT01721577 Phase 1, Phase 2 AXL1717
7 Temozolomide Plus Radiation Therapy in Treating Patients With Newly Diagnosed Anaplastic Oligodendrogliomas or Mixed Anaplastic Oligoastrocytomas Completed NCT00033280 Phase 2 temozolomide
8 Temozolomide in Relapsed or Advanced Anaplastic Oligodendroglioma and Oligoastrocytoma: Single-arm, Phase II Trial Completed NCT01847235 Phase 2 Temozolomide
9 BIBF 1120 for Recurrent High-Grade Gliomas Completed NCT01380782 Phase 2 BIBF 1120
10 Cilengitide in Treating Younger Patients With Recurrent or Progressive High-Grade Glioma That Has Not Responded to Standard Therapy Completed NCT00679354 Phase 2 cilengitide
11 Phase (Ph) II Bevacizumab + Erlotinib for Patients (Pts) With Recurrent Malignant Glioma (MG) Completed NCT00671970 Phase 2 Bevacizumab and Erlotinib
12 Study of Capecitabine to Treat Recurrent High Grade Gliomas Completed NCT00717197 Phase 2 Capecitabine
13 Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA Recruiting NCT02800486 Phase 2 Intra-arterial Cetuximab;Intra-arterial Mannitol
14 Vorinostat and Radiation Therapy Followed by Maintenance Therapy With Vorinostat in Treating Younger Patients With Newly Diagnosed Diffuse Intrinsic Pontine Glioma Active, not recruiting NCT01189266 Phase 1, Phase 2 Vorinostat
15 Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer Active, not recruiting NCT00445965 Phase 2
16 Photodynamic Therapy (PDT) For Recurrent High Grade Gliomas Active, not recruiting NCT01966809 Phase 2 Photofrin photodynamic therapy.
17 Crizotinib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma Active, not recruiting NCT00939770 Phase 1, Phase 2 crizotinib
18 A Phase II Study of Temozolomide and O6-Benzylguanine (O6-BG) in Patients With Temozolomide-Resistant Anaplastic Glioma Terminated NCT00389090 Phase 2 Temozolomide and O6-Benzylguanine
19 Phase I / II Vorinostat, Erlotinib and Temozolomide for Recurrent Glioblastoma Multiforme (GBM) Terminated NCT01110876 Phase 1, Phase 2 Vorinostat;Erlotinib;Temozolomide
20 Irinotecan Plus Lenalidomide in Adult Patients With Recurrent Glioblastoma Multiforme (Phase II) Withdrawn NCT02369367 Phase 2 Irinotecan;Lenalidomide
21 Phase I/II Cabazitaxel for Recurrent Malignant Glioma Withdrawn NCT01740570 Phase 1, Phase 2 Cabazitaxel
22 Photodynamic Therapy With Porfimer Sodium in Treating Patients With Refractory Brain Tumors Unknown status NCT00002647 Phase 1 verteporfin
23 Study of a Retroviral Replicating Vector Given Intravenously to Patients Undergoing Surgery for Recurrent Brain Tumor Completed NCT01985256 Phase 1 Toca FC
24 Study of a Retroviral Replicating Vector Combined With a Prodrug to Treat Patients Undergoing Surgery for a Recurrent Malignant Brain Tumor Completed NCT01470794 Phase 1 Toca FC
25 A Study of a Retroviral Replicating Vector Combined With a Prodrug Administered to Patients With Recurrent Malignant Glioma Completed NCT01156584 Phase 1 Toca FC
26 Sorafenib in Newly Diagnosed High Grade Glioma Completed NCT00884416 Phase 1 Sorafenib dose escalation
27 Gene Therapy in Treating Patients With Recurrent or Progressive Brain Tumors Completed NCT00004080 Phase 1
28 Cellular Immunotherapy Study for Brain Cancer Completed NCT01144247 Phase 1 alloreactive CTL
29 Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors Completed NCT01522820 Phase 1 Sirolimus
30 Vaccine Therapy and Sargramostim in Treating Patients With Malignant Glioma Completed NCT01250470 Phase 1 Montanide ISA-51/Survivin Peptide Vaccine
31 Bafetinib in Treating Patients With Recurrent High-Grade Glioma or Brain Metastases Completed NCT01234740 Phase 1 bafetinib
32 A Pilot Feasibility Study of Oral 5-Fluorocytosine and Genetically-Modified Neural Stem Cells Expressing E.Coli Cytosine Deaminase for Treatment of Recurrent High Grade Gliomas Completed NCT01172964 Phase 1 flucytosine
33 PH I Addition of Farnesyl Transferase Inhibitor to Temozolomide for Pts w Gr 3 & 4 Malignant Gliomas Completed NCT00612651 Phase 1 Temodar and SCH 66336
34 Ph I SU011248 + Irinotecan in Treatment of Pts w MG Completed NCT00611728 Phase 1 SU011248 & Irinotecan
35 Imetelstat Sodium in Treating Young Patients With Refractory or Recurrent Solid Tumors or Lymphoma Completed NCT01273090 Phase 1 imetelstat sodium
36 Pharmacokinetics (PK) Study of AC480 for Recurrent Glioma Completed NCT00979173 Phase 1 AC480
37 A Study of Motexafin Gadolinium and Temozolomide for the Treatment of Malignant Gliomas Completed NCT00080054 Phase 1 Motexafin Gadolinium Injection
38 A Study of Ad-RTS-hIL-12 With Veledimex in Subjects With Glioblastoma or Malignant Glioma Recruiting NCT02026271 Phase 1 veledimex
39 Phase 1b Study PVSRIPO for Recurrent Malignant Glioma in Children Recruiting NCT03043391 Phase 1
40 WEE1 Inhibitor AZD1775 and Local Radiation Therapy in Treating Children With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas Recruiting NCT01922076 Phase 1 Adavosertib
41 Neural Stem Cell Based Virotherapy of Newly Diagnosed Malignant Glioma Recruiting NCT03072134 Phase 1
42 Carboxylesterase-Expressing Allogeneic Neural Stem Cells and Irinotecan Hydrochloride in Treating Patients With Recurrent High-Grade Gliomas Recruiting NCT02192359 Phase 1 irinotecan hydrochloride
43 Palbociclib Isethionate in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors Recruiting NCT02255461 Phase 1 palbociclib isethionate
44 Hypofractionated Stereotactic Radiotherapy With Bevacizumab in the Treatment of Recurrent Malignant Glioma Active, not recruiting NCT01392209 Phase 1
45 Genetically Modified Neural Stem Cells, Flucytosine, and Leucovorin for Treating Patients With Recurrent High-Grade Gliomas Active, not recruiting NCT02015819 Phase 1 flucytosine;leucovorin calcium
46 Temozolomide and Ascorbic Acid in Treating Patients With Recurrent High-Grade Glioma Terminated NCT02168270 Phase 1 temozolomide
47 Plerixafor (AMD3100) and Bevacizumab for Recurrent High-Grade Glioma Terminated NCT01339039 Phase 1 Plerixafor;Plerixafor;Bevacizumab;Plerixafor
48 Oncolytic HSV-1716 in Treating Younger Patients With Refractory or Recurrent High Grade Glioma That Can Be Removed By Surgery Terminated NCT02031965 Phase 1 dexamethasone
49 Irinotecan Plus Lenalidomide in Adult Patients With Recurrent Glioblastoma Multiforme: Phase I Terminated NCT00671801 Phase 1 Irinotecan;Lenalidomide
50 Ph. I Dasatinib/Protracted Temozolomide in Recurrent Malignant Glioma Withdrawn NCT00734864 Phase 1 enzyme-inducing anti-epileptic drugs;enzyme-inducing anti-epileptic drugs

Search NIH Clinical Center for Anaplastic Oligoastrocytoma

Genetic Tests for Anaplastic Oligoastrocytoma

Anatomical Context for Anaplastic Oligoastrocytoma

MalaCards organs/tissues related to Anaplastic Oligoastrocytoma:

41
Brain, Spinal Cord, Myeloid, Bone Marrow, Bone

Publications for Anaplastic Oligoastrocytoma

Articles related to Anaplastic Oligoastrocytoma:

(show all 21)
# Title Authors Year
1
Primary spinal cord anaplastic oligoastrocytoma presenting with paraplegia. ( 26851716 )
2016
2
Focal seizure induced by preoperative navigated transcranial magnetic stimulation in a patient with anaplastic oligoastrocytoma. ( 28017645 )
2016
3
A case of medulloblastoma in adult patient affected by anaplastic oligoastrocytoma. ( 27329275 )
2016
4
Solitary "aggressive" leptomeningeal anaplastic oligoastrocytoma. ( 26318905 )
2015
5
Opsoclonus-myoclonus syndrome in a patient with an anaplastic oligoastrocytoma. ( 25864100 )
2015
6
Anaplastic oligoastrocytoma: is molecular stratification based on 1p/19q status alone appropriate? ( 25555564 )
2015
7
Treatment updates regarding anaplastic oligodendroglioma and anaplastic oligoastrocytoma. ( 25523732 )
2014
8
Successful use of metronomic vinblastine and fluorothymidine pet imaging for the management of intramedullary spinal cord anaplastic oligoastrocytoma in a child. ( 25489269 )
2014
9
1p/19q codeletion and IDH1/2 mutation identified a subtype of anaplastic oligoastrocytomas with prognosis as favorable as anaplastic oligodendrogliomas. ( 23486687 )
2013
10
Anaplastic oligoastrocytoma in Turcot syndrome. ( 19495563 )
2009
11
Prognosis in patients with anaplastic oligoastrocytoma is associated with histologic grade. ( 17431544 )
2007
12
Anaplastic oligoastrocytoma: previous treatment as a possible cause in a child with acute lymphoblastic leukemia. ( 17043901 )
2007
13
Isolation and characterization of stem cell-like precursor cells from primary human anaplastic oligoastrocytoma. ( 17660801 )
2007
14
Positive reaction for cysticercosis and multicentric anaplastic oligoastrocytoma. ( 15778869 )
2006
15
Higher dosing of temozolomide? Regression of an anaplastic oligoastrocytoma over more than three years. ( 16292485 )
2006
16
Neoadjuvant temozolomide followed by complete resection of a 1p- and 19q-deleted anaplastic oligoastrocytoma: case study. ( 15701287 )
2005
17
Comparative genetic analysis of metachronous anaplastic oligoastrocytomas with extended recurrence-free interval. ( 15925987 )
2005
18
Cytoplasmic crystalline inclusions in a anaplastic oligoastrocytoma. ( 15471429 )
2004
19
Development of secondary anaplastic oligoastrocytoma after matched unrelated bone marrow transplantation in a child with acute myeloid leukemia. ( 12853693 )
2003
20
[Anaplastic oligoastrocytoma of the spinal cord: diagnostic difficulties. Case report]. ( 11253487 )
2000
21
Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. ( 10561351 )
1999

Variations for Anaplastic Oligoastrocytoma

Expression for Anaplastic Oligoastrocytoma

Search GEO for disease gene expression data for Anaplastic Oligoastrocytoma.

Pathways for Anaplastic Oligoastrocytoma

GO Terms for Anaplastic Oligoastrocytoma

Sources for Anaplastic Oligoastrocytoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....